ADMA BIOLOGICS, INC. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
ADMA BIOLOGICS, INC. (ADMA) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $64.43 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $64.43M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $65.61M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $76.64M; Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed $77.76M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $81.53M; Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed $81.53M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $64.43M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $65.61M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $76.64M 10-K · filed 2025-03-18 | $77.76M 10-K · filed 2024-02-28 |
| 2022-12-31 | $81.53M 10-K · filed 2024-02-28 | $81.53M 10-K · filed 2023-03-23 |
| 2021-12-31 | $73.04M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $59.11M 10-K · filed 2022-03-24 | |
| 2019-12-31 | $42.50M 10-K · filed 2021-03-25 | |
| 2018-12-31 | $26.08M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $29.14M 10-K · filed 2019-03-13 | |
| 2016-12-31 | $30.84M 10-K · filed 2018-03-29 | |
| 2015-12-31 | $25.83M 10-K · filed 2017-02-24 | |
| 2014-12-31 | $21.00M 10-K · filed 2016-03-23 | |
| 2013-12-31 | $16.79M 10-K · filed 2015-03-09 | |
| 2012-12-31 | $11.60M 10-K · filed 2014-03-28 | |
| 2011-12-31 | $10.27M 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |